openPR Logo
Press release

Metastatic Melanoma Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Evaxion, Biotech, InxMed, AiVita, Iovance, Viralytics, Merck, Neon Therapeutics, BioNTech, Cytovation, BMS

10-24-2023 06:42 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Metastatic Melanoma Pipeline Analysis (2023) Covering

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 75+ key pharma and biotech companies are working on 75+ pipeline drugs in the Metastatic Melanoma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Metastatic Melanoma Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Metastatic Melanoma Therapeutics Market.

The report provides a detailed description of the Metastatic Melanoma drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Metastatic Melanoma Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/metastatic-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Metastatic Melanoma Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Metastatic Melanoma therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Melanoma treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Metastatic Melanoma drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Metastatic Melanoma treatment market.

Learn More about the Clinical and Commercial Development Activities in the Metastatic Melanoma Therapeutics Domain @
https://www.delveinsight.com/report-store/metastatic-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Metastatic Melanoma Therapeutics Analysis
The treatment of Metastatic Melanoma focuses on prolonging survival, eliminating cancer, shrinking or stopping the growth of known metastases, and controlling symptomatic or risky sites of disease, thereby providing comfort. The treatment landscape of Metastatic melanoma comprises immunotherapy, targeted therapy, intralesional therapy, chemotherapy, and radiation therapy. However, surgery is also considered an option in some instances.

Over the past years, several therapies have been approved by the US FDA. Depending on the features of the tumor (location, stage, and genetic profile), the therapeutic options may be surgical resection, chemotherapy, radiotherapy, photodynamic therapy (PDT), immunotherapy, or targeted therapy. Yet, for individuals at Stages I-III, the most common treatment choice is surgical resection, and for solitary metastatic melanoma, metastasectomy remains the primary intervention.

Recently the US FDA approved OPDUALAG for patients with metastatic or inoperable melanoma, which consisted of two immunotherapy agents, relatlimab (anti-LAG-3) and nivolumab (anti-PD-1), which delayed time to cancer progression.

Several unmet needs are associated with melanoma, such as the need for prognostic biomarkers, raising awareness, better clinical research, monitoring toxicity of immune checkpoint inhibitors, and the need for neo-adjuvant therapy.

To further improve the treatment scenario, there are approx. 75+ key companies developing therapies for Metastatic Melanoma. Evaxion Biotech is leading the therapeutics market with its Metastatic Melanoma drug candidates in the most advanced stage of clinical development.

Metastatic Melanoma Companies in the Therapeutics Market Include:
• Evaxion Biotech
• InxMed
• AiVita Biomedical
• Iovance Biotherapeutics
• Viralytics
• Merck & Co.
• Neon Therapeutics
• BioNTech
• Bristol-Myers Squibb
• Ono Pharmaceuticals
• Cytovation AS
And Many Others

Emerging and Marketed Metastatic Melanoma Therapies Covered in the Report Include:
• EVX 01: Evaxion Biotech
• IN 10018: InxMed
• AV MEL 1: AiVita Biomedical
• EVX 01: Evaxion Biotech
• Lifileucel: Iovance Biotherapeutics
• Fianlimab: Regeneron Pharmaceuticals
• NKTR-214: Nektar Therapeutics
• IMO-2125: Idera Pharmaceuticals
• OBP 301: Oncolys BioPharma
• LN-144: Iovance Biotherapeutics
• Ampligen: Hemispherx Biopharma
• IPI-549 + Nivolumab: Infinity Pharmaceuticals
And Many More

Get an in-depth Assessment of the Emerging Therapies and Metastatic Melanoma Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/metastatic-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Metastatic Melanoma Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Route of Administration
Metastatic Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type
Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Request for Sample PDF to Understand More About the Metastatic Melanoma Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/metastatic-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Metastatic Melanoma Current Treatment Patterns
4. Metastatic Melanoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Metastatic Melanoma Late-Stage Products (Phase-III)
7. Metastatic Melanoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Metastatic Melanoma Discontinued Products
13. Metastatic Melanoma Product Profiles
14. Metastatic Melanoma Companies
15. Metastatic Melanoma Drugs
16. Dormant and Discontinued Products
17. Metastatic Melanoma Unmet Needs
18. Metastatic Melanoma Future Perspectives
19. Metastatic Melanoma Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/metastatic-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

------------------------------------------------------------------------------------------------------------------------------
Discover DelveInsight's Comprehensive Market Research and Consulting Services:
https://www.delveinsight.com/market-research

Elevate your industry insights with our comprehensive medical devices market assessment reports. Visit to gain a strategic edge through expert analysis and in-depth coverage of the latest trends, innovations, and market dynamics, at:
https://www.delveinsight.com/medical-devices

Empowering Cancer Care: DelveInsight's oncology consulting services offer personalized guidance and cutting-edge expertise to navigate the ongoing clinical, commercial, and regulatory developments, visit for more details:
https://www.delveinsight.com/oncology

Other Trending Healthcare Reports by DelveInsight
Pulmonology Devices Market
https://www.delveinsight.com/report-store/pulmonology-devices-market

Small Cell Lung Cancer Market
https://www.delveinsight.com/report-store/small-cell-lung-cancer-market

Bronchiectasis Market
https://www.delveinsight.com/report-store/bronchiectasis-market

Lennox Gastaut Syndrome Market
https://www.delveinsight.com/report-store/lennox-gastaut-syndrome-market

Holter Monitor Market
https://www.delveinsight.com/report-store/holter-monitor-market

Muscle Invasive Bladder cancer Market
https://www.delveinsight.com/report-store/muscle-invasive-bladder-cancer-market

Osteochondrodysplasia Market
https://www.delveinsight.com/report-store/osteochondrodysplasia-market

Anesthesia Machines Market
https://www.delveinsight.com/report-store/anesthesia-workstation-machines-market

Secondary Myelofibrosis Market
https://www.delveinsight.com/report-store/secondary-myelofibrosis-market

Guillain-Barre Syndrome (GBS) Market
https://www.delveinsight.com/report-store/guillain-barre-syndrome-gbs-market

Hepatitis A Market
https://www.delveinsight.com/report-store/hepatitis-a-market

Sickle Cell Disease Market
https://www.delveinsight.com/report-store/sickle-cell-disease-market

Mucinous Cystic Neoplasms (MCNs) Market
https://www.delveinsight.com/report-store/mucinous-cystic-neoplasms-mcns-market

Overt Hepatic Encephalopathy Market
https://www.delveinsight.com/report-store/overt-hepatic-encephalopathy-market

Familial Hypercholesterolemia Market
https://www.delveinsight.com/report-store/familial-hypercholesterolemia-market-report

Lateral Epicondylitis (Tennis Elbow) Disease Market
https://www.delveinsight.com/report-store/lateral-epicondylitis-tennis-elbow-disease-market

Diverticulitis Market
https://www.delveinsight.com/report-store/diverticulitis-market

Crows Feet Market
https://www.delveinsight.com/report-store/crows-feet-market

Helicobacter Pylori Infections Market
https://www.delveinsight.com/report-store/helicobacter-pylori-infections-market

Charcot-Marie-Tooth Disease Market
https://www.delveinsight.com/report-store/charcot-marie-tooth-disease-market

Neurovascular Thrombectomy Devices Market
https://www.delveinsight.com/report-store/neurovascular-thrombectomy-devices-market

Neurothrombectomy Devices Market
https://www.delveinsight.com/report-store/neurovascular-thrombectomy-devices-market

Stargardt Disease (STGD) Market
https://www.delveinsight.com/report-store/stargardt-disease-stgd-market

Venous Leg Ulcer Market
https://www.delveinsight.com/report-store/venous-leg-ulcer-market

Genital Herpes Market
https://www.delveinsight.com/report-store/genital-herpes-market-forecast

Idiopathic Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/idiopathic-thrombocytopenic-purpura-market

Morquio Syndrome Market
https://www.delveinsight.com/report-store/morquio-syndrome-market

Lymphoedema Market
https://www.delveinsight.com/report-store/lymphoedema-market

Neurotrophic Keratopathy Market
https://www.delveinsight.com/report-store/neurotrophic-keratopathy-market

Oncolytic Virus Cancer Therapy Market
https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-market

Orthostatic Hypotension Market
https://www.delveinsight.com/report-store/orthostatic-hypotension-market

Advanced Wound Care (AWC) Market
https://www.delveinsight.com/report-store/advanced-wound-care-market

Opioid-related Disorders Market
https://www.delveinsight.com/report-store/opioid-related-disorders-market

Ankylosing Spondylitis (AS) Market
https://www.delveinsight.com/report-store/ankylosing-spondylitis-as-market

Chronic Insomnia Market
https://www.delveinsight.com/report-store/chronic-insomnia-market

Microscopic Polyangiitis (MPA) Market
https://www.delveinsight.com/report-store/microscopic-polyangiitis-mpa-market

Esophageal Squamous Carcinoma Market
https://www.delveinsight.com/report-store/esophageal-squamous-carcinoma-market

Hypertrophic Scar Market
https://www.delveinsight.com/report-store/hypertrophic-scar-market

Chemotherapy Induced Neutropenia (CIN) Market
https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-market

Idiopathic Interstitial Pneumonia Market
https://www.delveinsight.com/report-store/idiopathic-interstitial-pneumonia-market

Diphtheria Market
https://www.delveinsight.com/report-store/diphtheria-market

Dyslipidemia Market
https://www.delveinsight.com/report-store/dyslipidemia-market

Thymus Cancer Market
https://www.delveinsight.com/report-store/thymus-cancer-market

Tendonitis Market
https://www.delveinsight.com/report-store/tendonitis-market

Alpha-Antitrypsin Deficiency Market
https://www.delveinsight.com/report-store/alpha-antitrypsin-deficiency-market

Factor XA Inhibitor Market
https://www.delveinsight.com/report-store/factor-xa-inhibitor-market

Undifferentiated Pleomorphic Sarcoma Market
https://www.delveinsight.com/report-store/undifferentiated-pleomorphic-sarcoma-market

Carcinoid Tumor Syndrome Market
https://www.delveinsight.com/report-store/carcinoid-tumor-syndrome-market

Primary Progressive Multiple Sclerosis (PPMS) Market
https://www.delveinsight.com/report-store/primary-progressive-multiple-sclerosis-ppms-market

Thalassemia Market
https://www.delveinsight.com/report-store/thalassemia-market

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Metastatic Melanoma Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Evaxion, Biotech, InxMed, AiVita, Iovance, Viralytics, Merck, Neon Therapeutics, BioNTech, Cytovation, BMS here

News-ID: 3261507 • Views:

More Releases from DelveInsight Business Research LLP

Genital Warts Pipeline Insights Report 2025 | DelveInsight
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market

All 5 Releases


More Releases for Metastatic

Key Trends Reshaping the Metastatic Bone Disease Market: Advancements in Targete …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Metastatic Bone Disease Market Size Growth Forecast: What to Expect by 2025? The market size for metastatic bone disease has seen a quick expansion in the past few years. This market will increase from a value of $17.14 billion in 2024 to $18.88 billion in 2025, with a compound
Emerging Trends Influencing The Growth Of The Metastatic Urothelial Carcinoma Ma …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries. How Big Is the Metastatic Urothelial Carcinoma Market Size Expected to Be by 2034? The market size for metastatic urothelial carcinoma has seen exponential growth recently. The market will expand from a worth of $1.18 billion in 2024 to $1.42 billion in 2025, with a compound annual growth rate (CAGR) of 20.2%.
Key Influencer in the Metastatic Cancer Drugs Market 2025: Surging Prevalence Of …
How Are the key drivers contributing to the expansion of the metastatic cancer drugs market? The escalation in the incidence of metastatic cancers will be a driving force for the expansion of the metastatic cancer drugs market. Metastatic cancer is a late-stage cancer that spreads across the body. As the number of metastatic cancer cases escalates, so does the creation of innovative drugs to treat various kinds of metastatic cancers. The
Prominent Metastatic Breast Cancer Treatment Market Trend for 2025: Advancements …
Which drivers are expected to have the greatest impact on the over the metastatic breast cancer treatment market's growth? The increasing occurrence of breast cancer is anticipated to boost the progression of the metastatic breast cancer treatment market. Breast cancer is a form of the disease that originates in the breast cells and is caused by abnormal cell growth in the breast, leading to the formation of a tumor. This alteration
Major Force in the Metastatic Bone Disease Market 2025: Impact Of Bone Cancer Pr …
How Will the Metastatic Bone Disease Market Grow, and What Is the Projected Market Size? The market size for metastatic bone disease has seen considerable growth in recent years. There is an expected increase from $17.14 billion in 2024 to $18.88 billion in 2025, with a compound annual growth rate (CAGR) of 10.1%. The substantial growth during the historical period can be credited to factors like rising aging population, heightened cancer
Combination Therapy Strategies for Metastatic Cancer
Metastatic cancer, where cancer cells spread from the primary tumor to distant organs, presents significant treatment challenges. Combination therapy strategies have emerged as a powerful approach to enhance treatment efficacy, overcome resistance, and improve patient outcomes in metastatic cancer. Download Report: https://www.kuickresearch.com/report-cancer-antibody-combinations-therapy-cancer-antibody-combination-monoclonal-antibodies-combination-drug-conjugate-antibodies-combination One of the primary goals of combination therapy in metastatic cancer is to target both the primary tumor and metastatic sites. This comprehensive approach can improve overall disease control